Sultan Çalışkan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sultan Çalışkan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Mehmet Kefeli
Department of Pathology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey
5 shared publications- Ozgur Mete
Department of Pathology, University Health Network, Toronto, Canada
3 shared publications Seda Gun
Department of Pathology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey
2 shared publications- Ahmet Özdemir
Ondokuz Mayıs University
1 shared publication Arif Kokcu
1 shared publication- Aysegul Atmaca
Department of Endocrinology and Metabolism, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye
1 shared publication
Latest Publications
- 5 October 2025
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 80, 152572
Diagnostic utility of imprint cytology in assessing surgical margins during laparoscopic partial nephrectomy
- 5 October 2025
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 80, 152572
Diagnostic utility of imprint cytology in assessing surgical margins during laparoscopic partial nephrectomy
- Open Access
- 30 April 2025
- Published by Amasya University in Sabuncuoglu Serefeddin Health Sciences
- Vol. 7 (1) , 22-28
IMMUNOHISTOCHEMICAL EVALUATION, MOLECULAR INVESTIGATION AND DIFFERENTIAL DIAGNOSIS OF A NOVEL ADIPOCYTOKINE CHEMERİN IN OVARIAN AND UTERINE CANCERS
Patients diagnosed with the following histological types of carcinoma were included in the study: ovarian serous carcinoma (n=16), ovarian endometrioid carcinoma (n=12), ovarian mucinous carcinoma (n=11), uterine serous carcinoma (n=12) and uterine endometrioid carcinoma (n=15). The study was conducted between 2014 and 2023. The study is based on the comparison of two groups of patients with differing levels of organ involvement. Following the extraction of serum from blood samples, the samples were stored in a temperature of -20°C. The measurement of serum chemerin levels was conducted by means of the ELISA method. In the immunohistochemical study, the sections obtained from the tissues in paraffin blocks were stained for chimerine with the Leica Bond max closed system automatic staining device and Bond polymer refine detection (DS9800, Buffalo Grove, United States) DAB compatible kit. In the immunohistochemical study, the presence or absence of chimerin expression in tumour cells was examined. In the group where such expression was observed, the percentage of staining in the cells was calculated. Furthermore, clinical, laboratory and radiological findings were obtained from the hospital system.
- 30 April 2025
- Published by Amasya University in Sabuncuoglu Serefeddin Health Sciences
- Vol. 7 (1) , 22-28
Open AccessIMMUNOHISTOCHEMICAL EVALUATION, MOLECULAR INVESTIGATION AND DIFFERENTIAL DIAGNOSIS OF A NOVEL ADIPOCYTOKINE CHEMERİN IN OVARIAN AND UTERINE CANCERS
Patients diagnosed with the following histological types of carcinoma were included in the study: ovarian serous carcinoma (n=16), ovarian endometrioid carcinoma (n=12), ovarian mucinous carcinoma (n=11), uterine serous carcinoma (n=12) and uterine endometrioid carcinoma (n=15). The study was conducted between 2014 and 2023. The study is based on the comparison of two groups of patients with differing levels of organ involvement. Following the extraction of serum from blood samples, the samples were stored in a temperature of -20°C. The measurement of serum chemerin levels was conducted by means of the ELISA method. In the immunohistochemical study, the sections obtained from the tissues in paraffin blocks were stained for chimerine with the Leica Bond max closed system automatic staining device and Bond polymer refine detection (DS9800, Buffalo Grove, United States) DAB compatible kit. In the immunohistochemical study, the presence or absence of chimerin expression in tumour cells was examined. In the group where such expression was observed, the percentage of staining in the cells was calculated. Furthermore, clinical, laboratory and radiological findings were obtained from the hospital system.
- Open Access
- 24 July 2024
- Published by Springer Nature in Endocrine Pathology
- Vol. 35 (3) , 185-193
Granulation Patterns of Functional Corticotroph Tumors Correlate with Tumor Size, Proliferative Activity, T2 Intensity-to-White Matter Ratio, and Postsurgical Early Biochemical Remission
Unlike somatotroph tumors, the data on correlates of tumor granulation patterns in functional TPIT lineage pituitary neuroendocrine tumors (corticotroph tumors) have been less uniformly documented in most clinical series. This study evaluated characteristics of 41 well-characterized functional corticotroph tumors consisting of 28 densely granulated corticotroph tumors (DGCTs) and 13 sparsely granulated corticotroph tumors (SGCTs) with respect to preoperative clinical and radiological findings, tumor proliferative activity (including mitotic count and Ki-67 labeling index), and postoperative early biochemical remission rates. The median (interquartile range (IQR)) tumor size was significantly larger in the SGCT group [16.00 (16.00) mm in SGCT vs 8.5 (9.75) mm in DGCT, p = 0.049]. T2-weighted signal intensity and T2 intensity (quantitative) did not yield statistical significance based on tumor granulation; however, the T2 intensity-to-white matter ratio was significantly higher in SGCTs (p = 0.049). The median (IQR) Ki-67 labeling index was 2.00% (IQR 1.00%) in the DGCT group and 4.00% (IQR 7.00%) in the SGCT group (p = 0.043). The mitotic count per 2 mm2 was higher in the SGCT group (p = 0.001). In the multivariate analysis, the sparse granulation pattern (SGCT) remained an independent predictor of a lower probability of early biochemical remission irrespective of the tumor size and proliferative activity (p = 0.012). The current study further supports the impact of tumor granulation pattern as a biologic variable and warrants the detailed histological subtyping of functional corticotroph tumors as indicated in the WHO classification of pituitary neuroendocrine tumors. More importantly, the assessment of the quantitative T2 intensity-to-white matter ratio may serve as a preoperative radiological harbinger of SGCTs.
- 24 July 2024
- Published by Springer Nature in Endocrine Pathology
- Vol. 35 (3) , 185-193
Open AccessGranulation Patterns of Functional Corticotroph Tumors Correlate with Tumor Size, Proliferative Activity, T2 Intensity-to-White Matter Ratio, and Postsurgical Early Biochemical Remission
Unlike somatotroph tumors, the data on correlates of tumor granulation patterns in functional TPIT lineage pituitary neuroendocrine tumors (corticotroph tumors) have been less uniformly documented in most clinical series. This study evaluated characteristics of 41 well-characterized functional corticotroph tumors consisting of 28 densely granulated corticotroph tumors (DGCTs) and 13 sparsely granulated corticotroph tumors (SGCTs) with respect to preoperative clinical and radiological findings, tumor proliferative activity (including mitotic count and Ki-67 labeling index), and postoperative early biochemical remission rates. The median (interquartile range (IQR)) tumor size was significantly larger in the SGCT group [16.00 (16.00) mm in SGCT vs 8.5 (9.75) mm in DGCT, p = 0.049]. T2-weighted signal intensity and T2 intensity (quantitative) did not yield statistical significance based on tumor granulation; however, the T2 intensity-to-white matter ratio was significantly higher in SGCTs (p = 0.049). The median (IQR) Ki-67 labeling index was 2.00% (IQR 1.00%) in the DGCT group and 4.00% (IQR 7.00%) in the SGCT group (p = 0.043). The mitotic count per 2 mm2 was higher in the SGCT group (p = 0.001). In the multivariate analysis, the sparse granulation pattern (SGCT) remained an independent predictor of a lower probability of early biochemical remission irrespective of the tumor size and proliferative activity (p = 0.012). The current study further supports the impact of tumor granulation pattern as a biologic variable and warrants the detailed histological subtyping of functional corticotroph tumors as indicated in the WHO classification of pituitary neuroendocrine tumors. More importantly, the assessment of the quantitative T2 intensity-to-white matter ratio may serve as a preoperative radiological harbinger of SGCTs.
- Open Access
- 1 April 2024
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 54 (2) , 116-119
Unusual Metastasis to Eyelid from Extraocular Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is an unusual skin tumor that has a significant rate of distant and local metastases. It is known that primary MCC of the eyelid usually occurs at the upper eyelid. Here we report an unusual case of MCC metastasis to the eyelid. A 63-year-old male was diagnosed with MCC three years earlier after initially presenting with a mass in his right thigh. After histopathological diagnosis, the patient received medical therapy. During treatment, he developed multiple distant metastases and a firm, purple, vascularized lesion on the upper eyelid. We confirmed the lesion was an eyelid metastasis of MCC by histopathological examination and imaging methods. This case shows that extraocular MCC can metastasize to the eyelids, particularly the upper eyelid, where primary periocular MCC usually appears.
- 1 April 2024
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 54 (2) , 116-119
Open AccessUnusual Metastasis to Eyelid from Extraocular Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is an unusual skin tumor that has a significant rate of distant and local metastases. It is known that primary MCC of the eyelid usually occurs at the upper eyelid. Here we report an unusual case of MCC metastasis to the eyelid. A 63-year-old male was diagnosed with MCC three years earlier after initially presenting with a mass in his right thigh. After histopathological diagnosis, the patient received medical therapy. During treatment, he developed multiple distant metastases and a firm, purple, vascularized lesion on the upper eyelid. We confirmed the lesion was an eyelid metastasis of MCC by histopathological examination and imaging methods. This case shows that extraocular MCC can metastasize to the eyelids, particularly the upper eyelid, where primary periocular MCC usually appears.
- Open Access
- 1 January 2022
- Published by Federation of Turkish Pathology Societies in Turkish Journal of Pathology
- Vol. 39 (3) , 212-217
Malignant perivascular epithelioid cell tumor (pecoma) of the uterus as part of the hereditary cancer syndrome: a case diagnosed with multiple malignancies
A perivascular epithelioid cell tumor (PEComa) is an uncommon mesenchymal tumor composed of perivascular epithelioid cells. These tumor cells show variable immunoreactivity for both melanocytic and myogenic markers. Occurrence of PEComa has been reported at various anatomical sites, including the gynecological tract, uterus being the most common. Although most patients have sporadic PEComas, a subset may be associated with the inactivation of TSC1 or TSC2 genes and the occurrence of TFE3 gene fusions. However, a relationship between PEComas and other tumors is rare. We report a 41-year-old female patient with malignant PEComa who was admitted to the hospital with a complaint of vaginal bleeding. Because she had previously been diagnosed with colorectal and breast carcinomas at an early age, we performed a comprehensive genetic analysis to identify molecular alterations present in her background that unveiled multiple malignancy predispositions. Next-generation sequencing (NGS) analysis revealed two heterozygous germline pathogenic variants in the ATM and TP53 genes and a heterozygous variant of unknown significance (VUS) in the BRCA2 gene. The patient was diagnosed with the Li-Fraumeni Syndrome owing to the medical and family history and also the presentation of a pathogenic mutation of the TP53 gene. There are very few case reports in the literature describing PEComa in the Li-Fraumeni syndrome, and this is the first report of a uterine PEComa in a patient with Li-Fraumeni syndrome.
- 1 January 2022
- Published by Federation of Turkish Pathology Societies in Turkish Journal of Pathology
- Vol. 39 (3) , 212-217
Open AccessMalignant perivascular epithelioid cell tumor (pecoma) of the uterus as part of the hereditary cancer syndrome: a case diagnosed with multiple malignancies
A perivascular epithelioid cell tumor (PEComa) is an uncommon mesenchymal tumor composed of perivascular epithelioid cells. These tumor cells show variable immunoreactivity for both melanocytic and myogenic markers. Occurrence of PEComa has been reported at various anatomical sites, including the gynecological tract, uterus being the most common. Although most patients have sporadic PEComas, a subset may be associated with the inactivation of TSC1 or TSC2 genes and the occurrence of TFE3 gene fusions. However, a relationship between PEComas and other tumors is rare. We report a 41-year-old female patient with malignant PEComa who was admitted to the hospital with a complaint of vaginal bleeding. Because she had previously been diagnosed with colorectal and breast carcinomas at an early age, we performed a comprehensive genetic analysis to identify molecular alterations present in her background that unveiled multiple malignancy predispositions. Next-generation sequencing (NGS) analysis revealed two heterozygous germline pathogenic variants in the ATM and TP53 genes and a heterozygous variant of unknown significance (VUS) in the BRCA2 gene. The patient was diagnosed with the Li-Fraumeni Syndrome owing to the medical and family history and also the presentation of a pathogenic mutation of the TP53 gene. There are very few case reports in the literature describing PEComa in the Li-Fraumeni syndrome, and this is the first report of a uterine PEComa in a patient with Li-Fraumeni syndrome.
- 23 April 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (3) , 376-378
Gastrointestinal bleeding due to giant gastric bezoar
Gastric bezoars occur in the stomach due to foreign body accumulation with an inability to pass through the pylorus. Major complications of bezoars include intestinal obstruction, gastric ulcer, gastric perforation, and bleeding. Many gastric bezoars can often be treated conservatively. Endoscopy has been commonly used in both the diagnosis and treatment of bezoars. We present a case that complained about abundant gastrointestinal bleeding as well as abdominal distension and was successfully treated with emergency gastric surgery after the failure of bleed control by endoscopic intervention due to giant gastric bezoar.
- 23 April 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (3) , 376-378
Gastrointestinal bleeding due to giant gastric bezoar
Gastric bezoars occur in the stomach due to foreign body accumulation with an inability to pass through the pylorus. Major complications of bezoars include intestinal obstruction, gastric ulcer, gastric perforation, and bleeding. Many gastric bezoars can often be treated conservatively. Endoscopy has been commonly used in both the diagnosis and treatment of bezoars. We present a case that complained about abundant gastrointestinal bleeding as well as abdominal distension and was successfully treated with emergency gastric surgery after the failure of bleed control by endoscopic intervention due to giant gastric bezoar.
- 18 March 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (SI-1) , 78-80
A case of Meckel’s diverticulum with life-threatening recurrent gastrointestinal bleeding in an adult
Meckel’s diverticulum is the most common congenital anomaly of the gastrointestinal system. It results from the incomplete closure of the omphalomesenteric canal in intrauterine life. It is mostly diagnosed in childhood with intestinal obstruction and bleeding. It is uncommon and often clinically silent in adults. Also, it is difficult to diagnose the patients with symptomatic Meckel’s diverticulum. We report a 28-year-old male who presented with life-threatening recurrent lower gastrointestinal (GI) bleeding and was operated with the diagnosis of Meckel’s diverticulum with duodenal ulcer.
- 18 March 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (SI-1) , 78-80
A case of Meckel’s diverticulum with life-threatening recurrent gastrointestinal bleeding in an adult
Meckel’s diverticulum is the most common congenital anomaly of the gastrointestinal system. It results from the incomplete closure of the omphalomesenteric canal in intrauterine life. It is mostly diagnosed in childhood with intestinal obstruction and bleeding. It is uncommon and often clinically silent in adults. Also, it is difficult to diagnose the patients with symptomatic Meckel’s diverticulum. We report a 28-year-old male who presented with life-threatening recurrent lower gastrointestinal (GI) bleeding and was operated with the diagnosis of Meckel’s diverticulum with duodenal ulcer.
- Open Access
- 1 January 2021
- Published by Federation of Turkish Pathology Societies in Turkish Journal of Pathology
- Vol. 38 (2) , 1-8
Pd-l1 expression in medullary thyroid carcinoma and its association with clinicopathological findings
Objective: Medullary thyroid carcinoma (MTC) is a rare tumor originating from parafollicular C cells. It has more aggressive biologic behavior than differentiated thyroid carcinomas, and it is insensitive to treatment with radioactive iodine. Vandetanib and cabozantinib are the newly approved tyrosine kinase inhibitors in advanced stages, but novel effective systemic therapeutics could be crucial and needed for the clinical management of these patients. We aimed to evaluate the Programmed death-ligand 1 (PD-L1) expression, which is a novel immunotherapy target, in our MTC cohort, and determine whether it has an association with clinical and pathological features.
- 1 January 2021
- Published by Federation of Turkish Pathology Societies in Turkish Journal of Pathology
- Vol. 38 (2) , 1-8
Open AccessPd-l1 expression in medullary thyroid carcinoma and its association with clinicopathological findings
Objective: Medullary thyroid carcinoma (MTC) is a rare tumor originating from parafollicular C cells. It has more aggressive biologic behavior than differentiated thyroid carcinomas, and it is insensitive to treatment with radioactive iodine. Vandetanib and cabozantinib are the newly approved tyrosine kinase inhibitors in advanced stages, but novel effective systemic therapeutics could be crucial and needed for the clinical management of these patients. We aimed to evaluate the Programmed death-ligand 1 (PD-L1) expression, which is a novel immunotherapy target, in our MTC cohort, and determine whether it has an association with clinical and pathological features.
- 7 January 2020
- Published by Springer Nature in Endocrine Pathology
- Vol. 31 (1) , 33-38
Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas
Medullary thyroid carcinomas display cytologic and architectural features that can simulate various primary and metastatic neoplasms. PAX8 immunoexpression in neuroendocrine neoplasms yielded antibody-dependent findings. Since the data regarding the expression profile of monoclonal PAX8 (MRQ-50) antibody is limited in large series of medullary thyroid carcinomas, this study investigated the expression profile of PAX8 (MRQ-50) in a series of 45 medullary thyroid carcinomas. PAX8 (MRQ-50) expression was noted in the thyroid follicular epithelial cells surrounding the tumor and was negative in all medullary thyroid carcinomas. In addition, twenty medullary thyroid carcinomas showed scattered entrapped thyroid follicular epithelial cells at the periphery of the tumor. Entrapped follicular epithelial cells were positive for PAX8 and thyroglobulin, and were negative for monoclonal CEA and calcitonin. A panel approach combining monoclonal antibodies to transcription factors, hormones and cell-specific peptides often assist diagnosticians in the workup of the cellular origin of a neuroendocrine neoplasm. Since PAX8 immunostaining is dependent on the antibody characteristics in neuroendocrine neoplasms, pathologists should be aware of the details of the PAX8 antibody used in a particular case.
- 7 January 2020
- Published by Springer Nature in Endocrine Pathology
- Vol. 31 (1) , 33-38
Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas
Medullary thyroid carcinomas display cytologic and architectural features that can simulate various primary and metastatic neoplasms. PAX8 immunoexpression in neuroendocrine neoplasms yielded antibody-dependent findings. Since the data regarding the expression profile of monoclonal PAX8 (MRQ-50) antibody is limited in large series of medullary thyroid carcinomas, this study investigated the expression profile of PAX8 (MRQ-50) in a series of 45 medullary thyroid carcinomas. PAX8 (MRQ-50) expression was noted in the thyroid follicular epithelial cells surrounding the tumor and was negative in all medullary thyroid carcinomas. In addition, twenty medullary thyroid carcinomas showed scattered entrapped thyroid follicular epithelial cells at the periphery of the tumor. Entrapped follicular epithelial cells were positive for PAX8 and thyroglobulin, and were negative for monoclonal CEA and calcitonin. A panel approach combining monoclonal antibodies to transcription factors, hormones and cell-specific peptides often assist diagnosticians in the workup of the cellular origin of a neuroendocrine neoplasm. Since PAX8 immunostaining is dependent on the antibody characteristics in neuroendocrine neoplasms, pathologists should be aware of the details of the PAX8 antibody used in a particular case.
- 1 April 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 32 (4) , 484-489
GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors
- 1 April 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 32 (4) , 484-489
GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors